Table 1.
Efficacy and side effect of different doses of GnRH antagonist at 24 weeks.
| Elagolix | Linzagolix | Relugolix | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Assessments | 150 mg Elaris-I |
200 mg Elaris-I |
150 mg Elaris-II |
200 mg Elaris-II |
75 mg | 100 mg | 200 mg | 40 mg CT Spirit-1 |
40 mg CT Spirit-2 |
| Pelvic Pain (OPP) | - | - | - | - | 70.8 | 66.7 | 77.3 | - | - |
| Dysmenorrhea (% responders) |
42.1 | 75.3 | 46.2 | 76.9 | 58.3 | 82.1 | 84.1 | 75.5 | 75.2 |
| NMPP (% responders) |
45.7 | 62.1 | 51.6 | 62.2 | 72.9 | 64.1 | 72.7 | 58.5 | 66 |
| BMD loss lumbar spine (%) | −0.32 | −2.41 | −0.72 | −2.49 | −0.80 | −1.37 | −2.60 | −0.70 | −0.78 |
| Hot flushes % | 23.7 | 42.3 | 22.6 | 47.6 | 19.0 | 28.8 | 45.6 | 10.4 | 13.6 |
Elagolix 150 mg once daily; elagolix 200 mg twice daily; linzagolix 75 mg, 100 mg and 200 mg once daily; and relugolix 40 mg plus add-back therapy once daily. OPP: overall pelvic pain; NMPP: non-menstrual pelvic pain.